Compare RUN & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | HAE |
|---|---|---|
| Founded | 2007 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2015 | 1991 |
| Metric | RUN | HAE |
|---|---|---|
| Price | $17.91 | $83.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | $20.63 | ★ $84.38 |
| AVG Volume (30 Days) | ★ 7.1M | 854.6K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.54 |
| EPS | N/A | ★ 3.44 |
| Revenue | ★ $2,316,656,000.00 | $1,327,850,000.00 |
| Revenue This Year | $18.66 | N/A |
| Revenue Next Year | $6.33 | $6.01 |
| P/E Ratio | ★ N/A | $24.30 |
| Revenue Growth | ★ 13.79 | N/A |
| 52 Week Low | $5.38 | $47.32 |
| 52 Week High | $22.44 | $87.32 |
| Indicator | RUN | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 70.71 |
| Support Level | $17.47 | $82.30 |
| Resistance Level | $18.91 | $87.32 |
| Average True Range (ATR) | 1.02 | 2.20 |
| MACD | -0.01 | -0.56 |
| Stochastic Oscillator | 20.10 | 61.70 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.